Carmen Criscitiello· @CarmenCriscit · X·· 2 天前评分70
正文 · 机器翻译
TALENT：在 HER2-low、HR+ 早期乳腺癌中采用 Tdxd 新辅助治疗——活性有限，pCR ~7%；加用 anastrozole 或调整化疗顺序均未改善疗效。有助于提醒我们，在以治愈为目标的治疗环境中，HER2-low 并不等同于 HER2 驱动型。#ESMO26 #ESMOAmbassadors @myESMO
201 浏览 · 7 赞 · 2 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Carmen Criscitiello · x.com